Akari Therapeutics (AKTX) Competitors $0.99 -0.02 (-1.98%) Closing price 08/8/2025 03:58 PM EasternExtended Trading$1.02 +0.03 (+3.54%) As of 08/8/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. SPRO, BHST, FATE, MCRB, IMRX, PLX, IKT, TARA, FTLF, and ANEBShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Spero Therapeutics (SPRO), BioHarvest Sciences (BHST), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Immuneering (IMRX), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Protara Therapeutics (TARA), FitLife Brands (FTLF), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Spero Therapeutics BioHarvest Sciences Fate Therapeutics Seres Therapeutics Immuneering Protalix BioTherapeutics Inhibikase Therapeutics Protara Therapeutics FitLife Brands Anebulo Pharmaceuticals Akari Therapeutics (NASDAQ:AKTX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Do institutionals and insiders believe in AKTX or SPRO? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 38.1% of Akari Therapeutics shares are owned by insiders. Comparatively, 5.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AKTX or SPRO? In the previous week, Spero Therapeutics had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 1 mentions for Spero Therapeutics and 0 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score. Company Overall Sentiment Akari Therapeutics Neutral Spero Therapeutics Neutral Which has more risk & volatility, AKTX or SPRO? Akari Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Which has preferable earnings and valuation, AKTX or SPRO? Akari Therapeutics has higher earnings, but lower revenue than Spero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/ASpero Therapeutics$47.98M2.55-$68.57M-$1.28-1.71 Do analysts prefer AKTX or SPRO? Akari Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 405.05%. Spero Therapeutics has a consensus price target of $5.00, indicating a potential upside of 128.31%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Akari Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is AKTX or SPRO more profitable? Akari Therapeutics has a net margin of 0.00% compared to Spero Therapeutics' net margin of -156.48%. Spero Therapeutics' return on equity of -123.50% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -213.59% -65.60% Spero Therapeutics -156.48%-123.50%-58.96% SummarySpero Therapeutics beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.86M$2.99B$5.47B$9.71BDividend YieldN/A2.28%4.59%4.12%P/E RatioN/A17.3230.1024.70Price / SalesN/A326.35458.36100.90Price / CashN/A40.7324.8428.01Price / Book1.188.888.525.76Net Income-$19.79M-$54.75M$3.27B$267.05M7 Day Performance-1.39%-2.07%4.65%3.13%1 Month Performance-12.44%1.81%0.96%1.27%1 Year Performance-72.58%8.71%36.43%22.83% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics3.2304 of 5 stars$0.99-2.0%$5.00+405.1%-72.6%$31.86MN/A0.009High Trading VolumeSPROSpero Therapeutics3.8441 of 5 stars$2.26-1.7%$5.00+121.2%+71.1%$128.59M$47.98M-1.77150Upcoming EarningsBHSTBioHarvest SciencesN/A$7.67-0.3%$13.67+78.2%N/A$126.28M$27.70M-15.34N/AFATEFate Therapeutics3.9809 of 5 stars$1.06-0.9%$3.83+261.6%-72.7%$122.63M$13.63M-0.71550News CoverageUpcoming EarningsAnalyst DowngradeMCRBSeres Therapeutics3.2319 of 5 stars$14.78+5.6%$73.67+398.4%-21.6%$122.17M$126.32M-3.21330Earnings ReportIMRXImmuneering3.4078 of 5 stars$3.43+1.8%$13.25+286.3%+198.2%$121.27MN/A-1.7560News CoverageGap DownPLXProtalix BioTherapeutics2.3773 of 5 stars$1.50+3.4%$15.00+900.0%+48.1%$119.41M$59.76M-11.54200News CoverageIKTInhibikase Therapeutics2.0947 of 5 stars$1.60+5.3%$6.50+306.3%+11.7%$118.95MN/A-0.606TARAProtara Therapeutics1.5498 of 5 stars$3.16+3.3%$20.50+548.7%+64.7%$118.06MN/A-1.8430FTLFFitLife Brands3.934 of 5 stars$13.05+4.4%$20.50+57.1%-3.1%$117.39M$64.47M15.5420News CoverageAnalyst RevisionANEBAnebulo Pharmaceuticals2.1861 of 5 stars$2.70-5.3%$5.50+103.7%+21.7%$117.09MN/A-10.384Positive NewsGap Up Related Companies and Tools Related Companies Spero Therapeutics Competitors BioHarvest Sciences Competitors Fate Therapeutics Competitors Seres Therapeutics Competitors Immuneering Competitors Protalix BioTherapeutics Competitors Inhibikase Therapeutics Competitors Protara Therapeutics Competitors FitLife Brands Competitors Anebulo Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale